Immunome Prices $400 Million Public Offering to Fuel Cancer Therapy Development
Bothell, Wash. – Immunome, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering novel targeted cancer therapies, announced today the successful pricing of an underwritten public offering of 18,625,000 shares of its common stock. The offering was priced at $21.50 per share, generating substantial capital for the company’s ambitious development pipeline. Immunome is set to receive approximately $400 million in gross proceeds before accounting for underwriting discounts, commissions, and other associated expenses.
The company has also granted the underwriters a 30-day option to purchase up to an additional 2,793,750 shares at the same public offering price, providing a potential further capital infusion. The transaction is anticipated to close on December 18, 2025, contingent upon the standard closing conditions being met.
This significant capital raise underscores investor confidence in Immunome’s scientific approach and its potential to deliver impactful treatments for cancer patients. The funds are strategically earmarked to advance Immunome’s portfolio of first-in-class and best-in-class targeted therapies, a critical step in moving these innovations from the laboratory to the clinic and ultimately to patients.
The offering was facilitated by a syndicate of leading financial institutions. Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities served as joint bookrunning managers. Wedbush PacGrow and LifeSci Capital acted as co-lead managers, underscoring the broad market appetite for Immunome’s growth story.
This offering was executed under a shelf registration statement on Form S-3, previously filed with and declared effective by the U.S. Securities and Exchange Commission. This regulatory pathway allows for efficient and timely capital raising, enabling companies to capitalize on favorable market conditions.
**Strategic Implications and Pipeline Focus:**
Immunome’s commitment to targeted oncology is evident in its robust pipeline. The company is actively developing therapies designed to precisely target cancer cells, minimizing collateral damage to healthy tissues – a hallmark of modern precision medicine. Key assets include:
* **Varegacestat:** A GSI (gamma-secretase inhibitor) therapy in late-stage clinical development, indicating significant progress towards potential market approval.
* **IM-1021:** A clinical-stage antibody-drug conjugate (ADC) targeting ROR1, a protein implicated in various cancers. ADCs represent a sophisticated approach, delivering potent cytotoxic agents directly to cancer cells.
* **IM-3050:** A fibroblast activation protein (FAP)-targeted radiotherapy that has recently received Investigational New Drug (IND) clearance, paving the way for human trials. FAP is increasingly recognized as a valuable target in the tumor microenvironment.
Beyond these advanced programs, Immunome is also cultivating a broad portfolio of early-stage ADCs targeting a range of undisclosed solid tumor indications. This diversified strategy reflects a deep understanding of oncology targets and therapeutic modalities, aiming to build a comprehensive franchise in cancer treatment.
The company’s leadership, comprised of individuals who have previously been instrumental in the design, development, and commercialization of groundbreaking therapies, including ADCs, provides a strong foundation for executing its ambitious plans. This seasoned expertise is a critical differentiator in the highly competitive and complex biopharmaceutical landscape.
The substantial capital raised through this offering positions Immunome to significantly accelerate the development timelines for its promising pipeline candidates. This includes funding ongoing clinical trials, expanding manufacturing capabilities, and potentially exploring new therapeutic avenues as scientific insights emerge. The success of this offering not only bolsters Immunome’s financial standing but also signals a positive outlook for the targeted oncology sector, highlighting the enduring investor interest in companies developing innovative solutions for unmet medical needs.
**About Immunome, Inc.:**
Immunome is a clinical-stage targeted oncology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. The company leverages its expertise to advance a pipeline of innovative therapeutics, drawing on a leadership team with a proven track record in designing, developing, and commercializing cutting-edge treatments, including antibody-drug conjugate therapies. Immunome’s pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. The company is also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/14632.html
